diacerein has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harahsheh, E; Hussein, S; Mohamed Kamel, GA | 1 |
| Boccardo, E; de Oliveira, PG; Durigon, EL; Lepique, AP; Sposito, AC; Termini, L | 1 |
2 other study(ies) available for diacerein and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1/TLR4/NF-κB and upregulating PPAR-γ signal.
Topics: Acetaminophen; Animals; Anthraquinones; Antioxidants; Chemical and Drug Induced Liver Injury; COVID-19; HMGB1 Protein; Humans; Liver; Male; NF-kappa B; PPAR gamma; Rats; Toll-Like Receptor 4 | 2022 |
Diacerein: A potential multi-target therapeutic drug for COVID-19.
Topics: Angiotensin-Converting Enzyme 2; Animals; Anthraquinones; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Evaluation, Preclinical; Host Microbial Interactions; Humans; Male; Mice, Inbred C57BL; Models, Biological; Oxidation-Reduction; Pandemics; Receptors, Coronavirus; SARS-CoV-2; Signal Transduction; Virus Replication | 2020 |